Related Experiment Videos
Endothelial progenitor cells: characterization, pathophysiology, and possible clinical relevance
Mihail Hristov1, Christian Weber
1Department for Molecular Cardiovascular Research, University Hospital Aachen, Pauwelsstrasse 30, 52074 Aachen, Germany. mhristov@ukaachen.de
Journal of Cellular and Molecular Medicine
|December 17, 2004
Summary
Adult bone marrow contains endothelial progenitor cells (EPCs) that form new blood vessels. While therapeutically promising for ischemic conditions, their differentiation and homing mechanisms require further investigation.
Area of Science:
- Cardiovascular Biology
- Stem Cell Research
- Regenerative Medicine
Background:
- Adult bone marrow and peripheral blood harbor unique progenitor cells.
- These cells, termed endothelial progenitor cells (EPCs), differentiate into mature endothelial cells.
- EPCs contribute to re-endothelialization and neo-vascularization, mimicking embryonal angioblasts.
Purpose of the Study:
- To characterize endothelial progenitor cells (EPCs).
- To explore the therapeutic potential of EPCs in neo-vascularization.
- To identify knowledge gaps regarding EPC differentiation and homing mechanisms.
Main Methods:
- Identification of EPCs using surface markers (CD133, CD34, VEGFR-2).
- Analysis of EPC marker expression changes during circulation.
- Review of recent clinical studies on EPC-based neo-vascularization.
Main Results:
- Early EPCs express CD133, CD34, and VEGFR-2, predominantly in bone marrow.
- Circulating EPCs downregulate progenitor markers and upregulate endothelial markers (VE-cadherin, eNOS, vWF).
- Low numbers of circulating EPCs in healthy individuals; influenced by various factors.
Conclusions:
- EPCs represent a promising cell type for therapeutic neo-vascularization.
- Clinical applications are emerging, but mechanisms of EPC differentiation and homing remain incompletely understood.
- Further research is needed to elucidate EPC behavior and optimize therapeutic strategies.